Photo by atikahakhtar from unsplash
Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear deposition of IgA along the cutaneous basement membrane. Clinically, LABD has a variable presentation characterized by tense… Click to show full abstract
Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear deposition of IgA along the cutaneous basement membrane. Clinically, LABD has a variable presentation characterized by tense vesiculobullous lesions on the trunk and extremities that often appear in a herpetiform arrangement or at the center of annular erythematous plaques. Omalizumab (Xolair; Genentech, South San Francisco, CA) is a monoclonal anti–immunoglobulin E (IgE) antibody that has been approved for chronic idiopathic urticaria (CIU). To date, omalizumab has not been reported to be of benefit in the treatment of LABD. However, omalizumab has been reported to improve control of other bullous dermatoses, particularly bullous pemphigoid.1
Journal Title: JAAD Case Reports
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!